Blood gene signatures may predict lymphoma treatment response
Simple blood tests may help veterinarians predict which dogs with diffuse large B-cell lymphoma are likely to respond well to treatment, according to a new Tufts University and UMass Chan Medical School study published March 25, 2026, in Scientific Reports. Researchers analyzed peripheral blood mononuclear cell gene expression from pet dogs enrolled in a prior clinical trial of a caninized anti-CD20 antibody, low-dose doxorubicin, and one of three investigational immunotherapy combinations. They found that higher expression of CD1E and CCL14 tracked with longer survival, while several interferon-stimulated genes and other immune-skewing markers were associated with poorer outcomes and earlier relapse. The team also reported proof-of-principle qPCR assays for several candidate markers, aiming toward a simpler point-of-care blood test. (now.tufts.edu)
Why it matters: For veterinary professionals, the study adds to growing evidence that liquid-biopsy-style tools could move canine lymphoma care toward earlier risk stratification and more tailored treatment planning. Canine diffuse large B-cell lymphoma is already an important comparative model for human disease, but in day-to-day practice the bigger implication is practical: a blood-based assay could eventually help identify poor responders before clinical relapse, support conversations with pet parents about prognosis, and inform decisions about whether to intensify therapy, change protocols, or monitor more closely. That said, this is still an early-stage research finding rather than a ready-to-use clinical test, and prior reviews of canine lymphoma biomarkers have emphasized that clinical validation, assay robustness, and real-world utility remain the main hurdles. (nature.com)
What to watch: The next step is external validation in larger cohorts and translation of these gene signatures into a standardized, clinic-friendly assay that can be tested prospectively in veterinary oncology practice. (nature.com)